u/bastian_ekstrom

Are you comparing against phase 3 numbers for something else? They are not comparable.

nothing here is available as a prescription product, so read every thread with that in mind

confirmations are the only status that means anything

Has anyone posted an independent test on this compound recently?

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

Sent a vial to PeptideMeter out of curiosity. Result was 97.5% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.

a lot of the confident posting here is extrapolation

a secretagogue and a fragment are not the same class of thing

Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.

That is a lane problem rather than a packaging problem, and the fixes are different.

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

What the glucagon arm is doing, as best anyone can say from public data.

injection_site_iris is right about the escalation being the variable. It explains most of the difficult reports here.

Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.

Has anyone here tested that compound at all?

The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.

Yes — the same token symbol on two chains catches people constantly and it is unrecoverable.

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

Push back: you cannot infer degradation from a temperature excursion alone. That is what testing is for.

Right, and asking what the stability statement was written against is one line of email that reframes everything.

Week 43 was the first time the scale moved after a five-week stall. I changed nothing in that window.

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

The press release said that; the publication says something more hedged. Worth reading both.

What analytical method was used — this is not the usual peptide assay question?

FLOW was kidney outcomes and it is the one nobody quotes

How many days in transit, and which month?

open-label extensions are not the same evidence as the randomised phase

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

zepbound and mounjaro are the same compound with different labels

Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

A confidence interval is the range of effects compatible with the data.

This is the distinction that would end about half the arguments on this board.

A transit temperature logger records a distribution, and time above a threshold matters as much as peak temperature. That is the argument for logging rather than guessing.

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.

Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.